Today is shaping up negative for Kymera Therapeutics, Inc. (NASDAQ:KYMR) shareholders, with the analysts delivering a substantial negative revision to this year’s forecasts. Both revenue and earnings per share (EPS) forecasts went under the knife, suggesting…

Click here to view the original article.